Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals, Inc. - Common Stock (NQ:PIRS)

13.60 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team
- Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical Officer - Shane Olwill, Ph.D., promoted to Chief Development Officer BOSTON, MA / ACCESSWIRE / August 3, 2021 / Pieris Pharmaceuticals, Inc.... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021
BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Alterity Therapeutics (NASDAQ:ATHE 
Via Benzinga
This Risky Micro-Cap Could Pay Off Big
Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace. 
Via The Motley Fool
Pieris Stock Moves Higher On €14.2M Grant For PRS-220 In Post-COVID Pulmonary Fibrosis
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor to treat... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Osmotica Pharmaceuticals (NASDAQ:OSMT) shares increased by 39.08% to $3.95 during Friday's pre-market session. The company's market cap stands at $247.7... 
Via Benzinga
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis
- PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis -... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Death
Exposures COVID-19 Death
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
45 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 27.11% to $4.5 during Thursday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
Gainers Marin Software Incorporated (NASDAQ: MRIN) jumped 58% to $2.70 after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne... 
Via Benzinga
3 Top Stocks Under $10
Are you looking for cheap stocks with a lot of upside? Check out Rolls-Royce, Pieris Pharmaceuticals, and Kahoot! 
Via The Motley Fool
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Aravive (NASDAQ:ARAV) stock moved upwards by 21.61% to $6.47 during Thursday's pre-market session. The company's market cap stands at $131.9 million. Arcus... 
Via Benzinga
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
21 Stocks Moving in Monday's Pre-Market Session
Gainers Raven Industries, Inc. (NASDAQ: RAVN) rose 47.2% to $56.86 in pre-market trading. CNH Industrial N.V (NYSE: CNHI) announced plans to acquire Raven Industries for $58 per... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Constellation (NASDAQ:CNST) shares moved upwards by 66.55% to $33.71 during Wednesday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
60 Biggest Movers From Yesterday
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday after the company announced plans to acquire a Alabama refinery and related... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Rezolute (NASDAQ:RZLT) shares rose 46.68% to $11.28 during Thursday's regular session. As of 12:30 EST, Rezolute's stock is trading at a volume of 1.4... 
Via Benzinga
41 Stocks Moving In Thursday's Mid-Day Session
Gainers 1847 Goedeker Inc. (NYSE: GOED) shares jumped 156.5% to $11.08 after dropping over 8% on Wednesday. Vertex Energy, Inc. (NASDAQ: VTNR) jumped 117% to $3.8604 after the... 
Via Benzinga
PIRS Stock: The Big News That Has Pieris Pharma Shares Rising Today
Pieris Pharmaceuticals (PIRS) stock is rising higher on Wednesday after announcing a collaboration agreement with Genentech. 
Via InvestorPlace
Pieris Pharmaceuticals Surges On The Stock Market After Agreement With Genentech
During yesterday's session, Pieris Pharmaceuticals (PIRS) soared in the financial markets after reaching a collaboration agreement with Genentech, in an operation that could be valued at $1.4 billion. 
Via Talk Markets
Where Will The Pieris Pharmacuetical Stock Rally End?
Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) on Tu... 
Via Benzinga
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 20.74% to $4.54 during Wednesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers Nabriva Therapeutics plc (NASDAQ: NBRV) rose 48.8% to $2.20 in pre-market trading. Sinovant Sciences and Nabriva Therapeutics disclosed topline results from Phase 3 trial... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.